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Introduction {#sec007}
============

Heart failure (HF) is a chronic clinical syndrome that affects more than 2% of the population. The number of HF patients is expected to rise significantly in coming years \[[@pone.0221434.ref001]\]. These patients have a high mortality rate and hospitalization is frequent.

Hospital admission rates for HF patients have been consistently high in recent decades. HF is the number one cause of hospital admission for patients over 65. Care of HF patients consumes 2% of the health budget and over 70% of the expense is due to the hospital care received by these patients \[[@pone.0221434.ref002]\].

Predictive models to identify risk factors for hospital readmission have been developed to prevent the re-hospitalization of these patients \[[@pone.0221434.ref003]--[@pone.0221434.ref006]\]. These studies have become more frequent over the last 10 years and are most prevalent in the United States, some featuring data from clinical trials, others using data from administrative databases and most focusing on hospital populations, including patients who have been hospitalized for HF.

The patients included in clinical trials are different from HF patients in the community \[[@pone.0221434.ref007]\]. While in the community, more than 80% of HF patients fall into NYHA functional class I-II, but patients in functional class III-IV are included in clinical trials. Omissions and registration errors are frequent in studies that use administrative databases.

Different types of factors have been studied as possible causes of hospitalization: sociodemographic, clinical, psychosocial and health system. A high number of risk factors for the hospitalization have been identified \[[@pone.0221434.ref008]\] but results are inconsistent. Clinical variables have been the focus of most studies but in the case of hospitalization they have a low---mild explanatory capacity. The discrimination capacity, measured by the C-statistic, is in the 0.6 to 0.8 range.

Most studies use 30 days as the reference period for rehospitalization, some have a 180-day reference period and only a few seek to predict hospitalization within a year's time. HF rehospitalization studies with short periods such as 30 days, mainly analyse the quality of hospital care received by HF patients, while studies with rehospitalization reference periods of one year assess continuity of care and the complete healthcare process.

Most studies analyse readmissions related to HF. However, in population studies, HF-related hospitalization only accounts for 16.5% of the cases; 21% are due to other cardiovascular diseases, and in more than 60% of the cases they are due to non-cardiovascular causes \[[@pone.0221434.ref009]\].

Considering that HF patients are complex and have a high comorbidity rate \[[@pone.0221434.ref010]\], an analysis of hospital admissions for all causes over a long period can help to understand the role played by comorbidity and the entire healthcare process, including continuity, in the admission rates of these patients.

The aim of this study is to develop and internally validate a predictive model for hospital admission in a year's time for any non-programmed cause, in patients with heart failure receiving primary care.

Methods {#sec008}
=======

This is part of a broader study whose methodology has been previously described \[[@pone.0221434.ref011]\]. This is a prospective cohort study conducted in two cities of the Community of Madrid which together have a population of 132 851. The study includes all patients over 18 diagnosed with HF, treated at the seven health centres that exist in the two municipalities.

Inclusion criteria {#sec009}
------------------

1\) patients who meet the Framingham criteria for HF diagnosis; 2) left ventricular ejection fraction (LVEF) less than 50% or significant structural lesion and/or diastolic dysfunction; patients who met the Framingham criteria and who had an echocardiographic study performed in the six months prior to inclusion were also included, and 3) informed consent of the patient to participate in the study.

Exclusion criteria {#sec010}
------------------

1\) institutionalized patients; 2) patients with a terminal illness other than HF; and 3) patients with a life expectancy of under 6 months.

Determinations {#sec011}
--------------

a\) Dependent variable: Unplanned hospitalization in the 12 months following inclusion in the study; b) Predictive variables: 1) disability, measured using version 2 of the 36-item World Health Organization Disability Assessment questionnaire (WHODAS-2) \[[@pone.0221434.ref012]\], obtaining a global score and a score in each of the six domains covered by the questionnaire: understanding and communication (UCA), getting around (GAR), self-care (SCA), getting along with people (GAP), life activities (LAC), and participation in society (PSO); 2) quality of life, measured by the Minnesota Living with Heart Failure Questionnaire (MLHFQ), obtaining a global score and a score in each of the two domains included in the questionnaire: physical and emotional \[[@pone.0221434.ref013]\]; 3) In addition to the questionnaire scores, the following variables were also analysed: age, sex, marital status, living alone, work situation, educational level, NYHA functional status, left ventricular ejection fraction (LVEF), amount of time since heart failure was first diagnosed, body mass index (BMI), blood pressure, use of drugs, comorbidity and hospitalization for any unplanned reason in the year prior to inclusion.

For the purposes of the multivariate analysis, WHODAS-2 scores were recoded into two categories: mild / moderate disability v. severe / extreme disability. NYHA functional class was recoded into two categories: class I-II and class III-IV. Educational level was divided into two categories: low (compulsory education, up to age 16) and medium / high (vocational training and university studies).

The initial evaluation consisted of a consultation with the physician and another with the nurse. In the visit with the general practitioner: the GP verified whether patients had an ECHO performed in the previous six months, assessed their baseline situation, checked inclusion and exclusion criteria, Framingham criteria, NYHA functional class and drug treatment; an echocardiogram and proBNP determination were also requested, where necessary. Nursing staff assessed patients' functional status (WHODAS-2) and quality of life (MLHFQ)

To establish predictive models based initially on 31 variables (not all included in the final model), a sample of 250 patients was considered sufficient, with an estimated hospitalization rate of 24% in the first 12 months \[[@pone.0221434.ref014],[@pone.0221434.ref015]\].

Development phase of the predictive model {#sec012}
-----------------------------------------

Logistic regression analysis was used to estimate the correlation between predictors and outcome, unplanned hospitalization in 12 months. The predictive model was built in several steps. 1) The initial examination included a set of 31 predictors ([Table 1](#pone.0221434.t001){ref-type="table"}). The relationship between a predictor and admission to hospital was estimated using a crude odds ratio, area under a receiver operating characteristic (AUROC) curve and R^2^. 2) The full model with 31 predictors was developed using penalized maximum likelihood estimation to directly correct the model for over-optimism. It was further simplified by decreasing the number of predictors based on recommendations found in the literature \[[@pone.0221434.ref016]\]. Interaction analysis was performed but no significant interaction was found. 3) Discrimination of this final model was quantified via an AUROC curve. Discrimination describes the ability of the prognostic model to distinguish patients with the outcome from those without the outcome. Predictive ability was determined using Nagelkerke\'s R^2^ and the Brier score index. Nagelkerke's R^2^ is the amount of variability in outcomes that is explained by the prediction model while the Brier score is a performance measurement quantifying the gap between observed and predicted outcome. Lastly, calibration was tested with the Hosmer-Lemeshow test for goodness of fit. Statistical analyses were performed using the R Regression Modeling Strategies package version 3.6--3.

10.1371/journal.pone.0221434.t001

###### Description of predictor variables.

![](pone.0221434.t001){#pone.0221434.t001g}

                                        Overall         Not Hospitalized   Hospitalized    p-value
  ------------------------------------- --------------- ------------------ --------------- ---------
  n                                     251             187                64              
  No EDC CHRONIC (mean (sd))            7.40 (2.85)     7.32 (2.86)        7.65 (2.84)     0.423
  TIME_EVOLUTION (mean (sd))            4.89 (6.00)     5.00 (6.38)        4.55 (4.77)     0.608
  PREVIOUS HOSPITALIZATION %            92 (36.8)       62 (33.3)          30 (46.9)       0.074
  AGE (mean (sd))                       74.86 (9.97)    74.18 (10.01)      76.86 (9.64)    0.063
  WOMEN (%)                             139 (55.4)      101 (54.0)         38 (59.4)       0.549
  NYHA III---IV (%)                     51 (20.3)       29 (15.5)          22 (34.4)       0.002
  LIVE ALONE (%)                        52 (20.7)       37 (19.8)          15 (23.4)       0.657
  MEDIUM / HIGH EDUCATIONAL LEVEL (%)   37 (14.7)       31 (16.6)          6 (9.4)         0.231
  EMPLOYMENT SITUATION (%)                                                                 0.668
  1                                     93 (37.1)       69 (36.9)          24 (37.5)       
  2                                     140 (55.8)      103 (55.1)         37 (57.8)       
  3                                     18 (7.2)        15 (8.0)           3 (4.7)         
  BMI (mean (sd))                       30.88 (6.12)    30.98 (5.86)       30.58 (6.87)    0.659
  DIABETES                              100 (39.8)      67 (35.8)          33 (51.6)       0.038
  COPD (%)                              35 (13.9)       19 (10.2)          16 (25.0)       0.006
  CORONARY HEART DISEASE %              62 (24.7)       47 (25.1)          15 (23.4)       0.917
  ATRIAL FIBRILLATION (%)               141 (56.2)      101 (54.0)         40 (662.5)      0.300
  STROKE (%)                            43 (17.1)       28 (15.0)          15 (23.4)       0.174
  LVEF (mean (sd))                      58.04 (12.38)   57.04 (12.35)      61.06 (12.12)   0.038
  ACE/ARB = 1 (%)                       177 (70.5)      134 (71.7)         43 (67.2)       0.604
  BETA BLOQUERS (%)                     142 (56.6)      111 (59.4)         31 (48.4)       0.169
  DIURETIC (%)                          208 (82.9)      153 (81.8)         55 (85.9)       0.574
  CALCIUM CHANNEL BLOCKERS (%)          65 (25.9)       46 (24.6)          19 (29.7)       0.524
  DIGOXIN (%)                           65 (25.9)       46 (24.6)          19 (29.7)       0.524
  PHYSICAL MLHFQ (mean (sd))            16.24 (10.24)   15.26 (10.06)      19.09 (10.04)   0.010
  EMOTIONAL MLHFQ (mean (sd))           6.41 (6.26)     5.61 (5.88)        8.73 (6.79)     0.001
  TOTAL MLHFQ (mean (sd))               24.25 (16.47)   22.20 (15.64)      30.25 (17.47)   0.001
  UCA WHODAS SEVERE / EXTREME (%)       33 (13.2)       21 (11.3)          12 (18.8)       0191
  GAR WHODAS SEVERE / EXTREME (%)       93 (37.2)       63 (33.7)          30 (47.6)       0.068
  SCA WHODAS SEVERE / EXTREME (%)       36 (14.4)       20 (10.8)          16 (25.0)       0.009
  GAP WHODAS SEVERE / EXTREME (%)       28 (11.2)       18 (9.7)           10 (15.6)       0.290
  LAC WHODAS SEVERE / EXTREME (%)       101 (40.4)      64 (34.4)          37 (57.8)       0.002
  PSO WHODAS SEVERE / EXTREME (%)       61 (24.4)       34 (18.3)          27 (42.2)       0.001
  TOTAL WHODAS SEVERE / EXTREME (%)     43 (17.1)       26 (13.9)          17 (26.6)       0.033

EDC: Expanded diagnostic clusters. NYHA: New York Heart Association. Body Mass Index. LVEF: Left Ventricular Ejection Fraction. ACE/ARB: Ratio ACE Inhibitors /Angiotensin Receptor Blockers. MLHFQ: Minnesota Living with Heart Failure Questionnaire. WHODAS: World Health Organization Assessment Schedule. UAC: Understanding and Communication. GAR: Getting around. SCA: Self-Care. GAP: Getting along with people. LAC: Life activities. PSO: Participation in society

Internal validation phase {#sec013}
-------------------------

Internal validation was evaluated using the bootstrapping technique, simulating 1 000 samples with 251 subjects similar to the original sample. The predictive ability of the model was evaluated internally based on discrimination (AUROC curve), measures of overall performance (Nagelkerke\'s R^2^ and the Brier score index) and calibration \[[@pone.0221434.ref017]\]. Calibration of the model was assessed graphically and estimated with the calibration intercept and slope. In case of a perfect fit between the model and the data, the calibration intercept is equal to 0 and slope is equal to 1.

The study was approved by the Clinical Research Ethics Committee of La Princesa University Teaching Hospital, and informed consent in writing was obtained from all patients before being enrolled.

Results {#sec014}
=======

The performance measures of predictive model used to establish the validity and utility were AUROC curve, Nagelkerke\'s R2 and the Brier score index. Robustness of performance measures of modes were evaluated using internal validation using bootstrap method.

278 patients were recruited, 27 of whom were excluded for the following reasons: 21 because after consulting the physician they left without meeting with the nurse, 1 due to CRD registration errors and 5 patients because at the time of this analysis, 12 months had not yet gone by since the date of their inclusion. The excluded patients were similar to those analysed in terms of age, sex, and NYHA functional class.

Of the 251 patients included in the study, 64 (25.5%) were admitted to hospital for some unplanned reason in the 12 months following the date of inclusion. The baseline characteristics of these patients are shown in [Table 1](#pone.0221434.t001){ref-type="table"}. The mean age was 74.86 ± 9.97, 55.4% were women, 20.3% of the patients were in NYHA functional class III-IV and the mean LVEF was 58.04 ± 12.35.

[Table 2](#pone.0221434.t002){ref-type="table"} shows the results of the univariate analysis of the predictor variables included in the study. The effect is expressed in terms of OR, with its confidence intervals and explanatory participation in the occurrence of the event, expressed by the R2N and in the discriminative capacity, expressed by the AUC. NYHA functional class, diabetes, COPD, LVEF, and the variables that measure quality of life and disability are the ones found to have a statistically significant effect on hospitalization.

10.1371/journal.pone.0221434.t002

###### Univariate analysis.
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                                      OR     OR 95% CI    p-value   R2N     ROC area
  ----------------------------------- ------ ------------ --------- ------- ----------
  No EDC CHRONIC                      1.04   0.94--1.15   0.4219    0.004   0.534
  TIME_EVOLUTION                      0.98   0.94--1.04   0.6072    0.002   0.497
  PREVIOUS HOSPITALIZATION            1.76   0.99--3.14   0.0541    0.022   0.568
  AGE                                 1.03   0.99--1.06   0.0647    0.021   0.581
  WOMEN                               1.24   0.70--2.21   0.4566    0.003   0.527
  NYHA III-IV                         2.85   1.49--5.46   0.0016    0.056   0.594
  LIVE ALONE                          1.24   0.62--2.45   0.5343    0.002   0.518
  MEDIUM / HIGH EDUC LEVEL            0.52   0.20--1.31   0.1664    0.012   0.536
  EMPLOYMENT SITUATION                                                      
      1. HOUSEWIFE                    Ref:   Ref:                   0.005   0.520
      2. RETIRED                      1.03   0.56--1.87   0.9158            
      3. EMPLOYEE                     0.57   0.15--2.16   0.4126            
  BMI                                 0.99   0.94--1.03   0.6579    0.001   0.525
  DIABETES                            1.90   1.07--3.38   0.027     0.028   0.579
  COPD                                2.94   1.41--6.16   0.0041    0.046   0.574
  ISCHEMIC CARDIOPATHOLOGY            0.91   0.46--1.77   0.7860    0.000   0.508
  ATRIAL FIBRILLATION                 1.42   0.79--2.54   0.2385    0.008   0.542
  STROKE                              1.74   0.86--3.51   0.1238    0.013   0.542
  LVEF                                1.03   1.00--1.05   0.0405    0.030   0.610
  ACE / ARB                           0.81   0.44--1.49   0.4988    0.003   0.522
  BETA BLOQUERS                       0.64   0.36--1.14   0.1295    0.013   0.555
  DIURETIC                            1.36   0.61--3.01   0.4515    0.003   0.521
  CALCIUM CHANNEL BLOCKERS            1.29   0.69--2.43   0.4232    0.004   0.525
  DIGOXIN                             1.29   0.69--2.43   0.4232    0.004   0.525
  PHYSICAL MLHFQ                      1.03   1.01--1.06   0.0106    0.039   0.614
  EMOTIONAL MLHFQ                     1.08   1.03--1.13   0.0008    0.065   0.630
  TOTAL MLHFQ                         1.03   1.01--1.05   0.0010    0.064   0.638
  UCA WHODAS SEVERE / EXTREME (%)     1.81   0.83--3.93   0.1322    0.013   0.537
  GAR WHODAS SEVERE / EXTREME (%)     1.79   1.00--3.19   0.493     0.023   0.570
  SCA WHODAS SEVERE / EXTREME (%)     2.76   1.33--5.75   0.0064    0.041   0.571
  GAP WHODAS SEVERE / EXTREME (%)     1.72   0.75--3.95   0.2021    0.009   0.529
  LAC WHODAS SEVERE / EXTREME (%)     2.61   1.46--4.67   0.0012    0.062   0.617
  PSO WHODAS SEVERE / EXTREME (%)     3.26   1.75--6.06   0.0002    0.079   0.620
  TOTAL WHODAS SEVERE / EXTREME (%)   2.24   1.12--4.47   0.0224    0.029   0.563

EDC: Expanded diagnostic clusters. NYHA: New York Heart Association. Body Mass Index. COPD: Chronic Obstructive Pulmonary Disease. LVEF: Left Ventricular Ejection Fraction. ACE/ARB: Ratio ACE Inhibitors /Angiotensin Receptor Blockers. MLHFQ: Minnesota Living with Heart Failure Questionnaire. WHODAS: World Health Organization Assessment Schedule. UAC: Understanding and Communication. GAR: Getting around. SCA: Self-Care. GAP: Getting along with people. LAC: Life activities. PSO: Participation in society.

The final multivariate model is presented in Tables [3](#pone.0221434.t003){ref-type="table"} and [4](#pone.0221434.t004){ref-type="table"} with an evaluation of performance in the development sample and in the internal validation process. The final model consists of four variables to predict the risk of hospitalization in 12 months: being in NYHA functional class III-IV, having diabetes, having COPD and the MLHFQ (quality of life questionnaire) emotional dimension score. A combination of the variables was used to determine predicted probability according to the formula (1/(1 + exp(-1\*(-2.2647 + 0.8996\*(NYHA_Cat2-1) + 1.1547\*COPD+ 0.0697\*MLHFQ_Emotional + 0.6632\*DIABETES)))). The model exhibited moderate discrimination capacity, AUC 0.723, with a Hosmer-Lemeshow test p-value of 0.815 and event variance explanatory capacity of 17%. Discrimination and calibration were maintained in the internal validation process ([Table 4](#pone.0221434.t004){ref-type="table"}).

10.1371/journal.pone.0221434.t003

###### Final multivariate model.

![](pone.0221434.t003){#pone.0221434.t003g}

  Model             Coefficient   OR     95% CI       p-value
  ----------------- ------------- ------ ------------ ---------
  Intercept         -2.2647                           0.0001
  NYHA III-IV       0.8996        2.46   1.23--4.91   0.0108
  DIABETES          0.6632        1.94   1.05--3.58   0.0336
  COPD              1.1547        3.17   1.45--6.94   0.0039
  EMOTIONAL MLHFQ   0.0697        1.07   1.02--1.12   0.0046

NYHA: New York Heart Association. Body Mass Index. COPD: Chronic Obstructive Pulmonary Disease. MLHFQ: Minnesota Living with Heart Failure Questionnaire.

10.1371/journal.pone.0221434.t004

###### Performance measurements.
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  ---------------------------------------------------------------------------------------------------------------------------
  Model                  ROC area\        Intersections   Recalibration slope   R2N      Brier Score   Hosmer-Lemeshow Test
                         (CI95%)                                                                       
  ---------------------- ---------------- --------------- --------------------- -------- ------------- ----------------------
  Final                  0.723\           0               1                     0.169    0.165         0.8149
                         (0.647--0.798)                                                                

  Internal validation\   0.706\           -0.0830         0.9116                0.1342   0.1734        
                         (0.631--0.783)                                                                
  ---------------------------------------------------------------------------------------------------------------------------

CI95%: Confidence Interval 95%

Based on the model developed ([Table 3](#pone.0221434.t003){ref-type="table"}) to estimate the risk of hospitalization at 12 months, an easy-to-use clinical prediction rule was constructed by assigning points to the coefficients. Thus, for a patient with NYHA III-IV, with COPD, Emotional MLHFQ score of 3, who does not have DIABETES would be assigned a total of 4 points, values obtained from [Table 5](#pone.0221434.t005){ref-type="table"} (3 for NYHA III-IV, 0 for COPD, 1 for MLHFQ_Emotional and 0 for DIABETES) and a hospital admission probability of 30.24% ([Table 6](#pone.0221434.t006){ref-type="table"}). Using the formula described above, a predicted probability of 23.93% is obtained.

10.1371/journal.pone.0221434.t005

###### Assignment of scores in the final model.
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                    Categories         Reference Category   Reference value   Example subject
  ----------------- ------------------ -------------------- ----------------- -----------------
  NYHA              Class III---IV                          3                 3
                    Class I---II       Reference            0                 X
  COPD              COPD                                    3                 X
                    NO COPD            Reference            0                 0
  EMOTIONAL MLHFQ   \< = 1             Reference            0                 X
                    \> = 2 - \< = 5                         1                 1
                    \> = 6 - \< = 11                        2                 X
                    \> = 12                                 3                 X
  DIABETES          DIABETES                                2                 X
                    NO DIABETES        Reference            0                 0
  Total points      4                                                         

NYHA: New York Heart Association. Body Mass Index. COPD: Chronic Obstructive Pulmonary Disease. MLHFQ: Minnesota Living with Heart Failure Questionnaire.

10.1371/journal.pone.0221434.t006

###### Risk associated with point totals.
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  Total points   Probability
  -------------- -------------
  0              0.0971
  1              0.1322
  2              0.1776
  3              0.2343
  4              0.3024
  5              0.3805
  6              0.4653
  7              0.5522
  8              0.6360
  9              0.7123
  10             0.7782
  11             0.8325

Discussion {#sec015}
==========

In our cohort of 251 HF patients, 64 were admitted for unplanned causes in a period of 12 months after inclusion in the study. 20.3% were patients who are in stage III-IV of the NYHA functional classification and with a mean LVEF of 58%. We started with a model that considers socio-demographic, clinical, functional capacity and quality of life variables as predictive factors. Four variables: NYHA functional class, diabetes, COPD and the MLHFQ emotional dimension score, were included in the final model to predict risk of hospitalization; three of these variables are part of the clinical information collected on a regular basis from the medical records of HF patients and quality of life; functional capacity is necessary given the impact of HF on these health dimensions \[[@pone.0221434.ref018]\]. Analysis of hospitalization over a 12-month period for any unplanned cause enables us to begin to assess the quality of hospital care and also to coordinate and provide ongoing care for these patients.

A large number of HF patient hospitalizations can be avoided \[[@pone.0221434.ref019]\]; identifying hospitalization risk factors can help reduce that number. The model we present has an acceptable discrimination capacity. However, its explanatory capacity of hospitalization variance is low, indicating that other relevant variables have been left out of the model. In general, models developed to predict HF patient hospitalization and mortality have been less accurate in predicting hospitalization. Hospitalization is more difficult to predict because it is an event that, in addition to being determined by the patient\'s clinical situation, depends on the characteristics of the healthcare system and the patient\'s support capacity.

In our study, 39.8% of patients have diabetes. HF and diabetes share some of the same physiopathological mechanisms \[[@pone.0221434.ref020]\]. The association of HF and diabetes increases the risk of hospitalization and death, compared to HF patients without diabetes \[[@pone.0221434.ref021]\]. Recommendations and CPGs have recently been published for the treatment of HF patients and diabetes \[[@pone.0221434.ref022],[@pone.0221434.ref023]\].

COPD is a common comorbidity in HF patients in our case and in other studies; 14% of patients have COPD. In our study, COPD increased the risk of hospital admission three-fold. COPD in HF patients is associated with higher comorbidity \[[@pone.0221434.ref024]\], increases the number family doctor visits \[[@pone.0221434.ref025]\], and increases the risk of hospitalization and death in these patients \[[@pone.0221434.ref026],[@pone.0221434.ref027]\]. Despite the peculiarities involved in the therapeutic management of these patients, neither the ESC's clinical practice guidelines for HF patients nor the GOLD guidelines contemplate management of this comorbidity in depth \[[@pone.0221434.ref028]\].

HF Patients are seriously limited in terms of their functional capacity and quality of life, which is why experts recommend including quality of life and functional capacity as endpoints in studies with HF patients \[[@pone.0221434.ref029]\]. In our study, 17% of patients have a severe/extreme global disability, measured with WHODAS 2; in some domains, such as ADL, severe/extreme disability reaches 40%.

Disability has been identified as a predictor of mortality and hospital admission in elderly patients \[[@pone.0221434.ref030],[@pone.0221434.ref031]\], in patients with complex ailments such as HF, these types of variables have greater predictive capacity for hospitalization than comorbidity \[[@pone.0221434.ref032]\]. However, the effect of disability has been less studied as a risk factor for hospital admission \[[@pone.0221434.ref031]\]. In our case, the limitation to perform the ADLs was a predictor of hospital admission in the univariate analysis, but the effect disappeared in the multivariate analysis.

Our study demonstrates an association between the emotional dimension of MLHFQ and hospital admission. Depression is a common mental disorder in HF patients that may explain the association found \[[@pone.0221434.ref033]\].

The study has limitations in terms of external validity. Since patients were recruited from family medical clinics, most were clinically stabilized HF patients with preserved ejection fraction (HFpEF) and low NYHA functional class, resulting in a unique sample.

The proposed model was validated internally but should be subjected to an external validation process in order to generalize the results.

We have not included biochemical or haematological parameters, some such as blood urea nitrogen has been shown as a relevant predictor of hospitalization in HF patients and its exclusion may have reduced the explanatory power of the model developed \[[@pone.0221434.ref004]\]. Patients\' clinical situation determined hospitalization, but the characteristics of the health system and the hospital\'s admission policy were also relevant factors that were not considered in this study.

In conclusion, we have developed a simple 12-month predictive hospitalization model based on four variables: NYHA functional class, diabetes, COPD and the emotional dimension of the MLHFQ scale, that has an acceptable discriminative capacity but that should be validated externally.
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